Please login to the form below

Not currently logged in
Email:
Password:

Constella

This page shows the latest Constella news and features for those working in and with pharma, biotech and healthcare.

FDA approves Synergy's constipation drug Trulance

FDA approves Synergy's constipation drug Trulance

Plecanatide's closest competitor in the market is Ironwood/Allergan's Linzess/Constella (linaclotide), described as a guanylate cyclase stimulant, which is approved for the treatment of constipation-predominant IBS in

Latest news

More from news
Approximately 3 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Oral biologics delivery still elusive Oral biologics delivery still elusive

    years. Among a newer generation of orally-delivered peptides is Ironwood Pharma's peptide drug Linzess/Constella (linaclotide) - which debuted in 2012 for constipation associated with irritable bowel syndrome.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • PharmaLex Group strengthens development consulting team PharmaLex Group strengthens development consulting team

    She also brings experience from contract research organisation SRA International, where she was senior director and global head of regulatory affairs, and Constella Group, where she was head of strategic drug

  • Ironwood promotes Dr Mark Currie Ironwood promotes Dr Mark Currie

    Linaclotide was approved as a treatment for irritable bowel syndrome last year by regulators in Europe, where the drug is marketed as Constella by Almirall.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics